T regulatory cells in cancer: recent advances and therapeutic potential.
AffiliationUniversity of Salford, School of Environment and Life Sciences, Centre for Biochemistry, Drug Design and Cancer Research, Salford, UK. email@example.com
MetadataShow full item record
AbstractIMPORTANCE OF THE FIELD: The active suppression of immune responses against tumor is a major barrier to the likely success of cancer immunotherapy. There is now compelling evidence implicating T regulatory cells (Tregs) as being key players driving immune suppression. Elevated frequencies of Tregs within the peripheral circulation and tumor microenvironment of cancer patients correlate with poor prognosis and reduced survival. Understanding the mechanism of Treg elevation is critical for the development of new approaches aiming to modulate the frequency and function of Tregs to enhance the efficacy of cancer immune-based therapies. AREAS COVERED IN THIS REVIEW: This review focuses on current knowledge concerning Tregs in cancer and discusses putative mechanisms which underlie the expansion of Tregs in cancer patients. Additionally, we review current strategies to deplete/suppress Treg activity, the limitations of these strategies and future perspective for improving their efficacy. WHAT THE READER WILL GAIN: An insight of the current aspects concerning Treg subsets in cancer and an overview of recent advances in the identification of Treg-specific markers, in addition to the potential strategies to target Tregs for enhancing antitumor immunity. TAKE HOME MESSAGE: Mechanisms by which Treg functions modulate the immune response to tumors are becoming further understood. However, specific markers to tumor-specific/induced Tregs are yet to be clearly identified, which is a major limitation in optimizing strategies to specifically target Tregs in cancer. Despite this, strategies aimed at modulating Tregs in patients are providing some early encouraging results supporting the overall concept and indicating that further studies are clearly warranted.
CitationT regulatory cells in cancer: recent advances and therapeutic potential. 2010, 10 (11):1573-86 Expert Opin Biol Ther
JournalExpert Opinion on Biological Therapy
- Role of naturally arising regulatory T cells in hematopoietic cell transplantation.
- Authors: Nguyen VH, Zeiser R, Negrin RS
- Issue date: 2006 Oct
- Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma.
- Authors: Klages K, Mayer CT, Lahl K, Loddenkemper C, Teng MW, Ngiow SF, Smyth MJ, Hamann A, Huehn J, Sparwasser T
- Issue date: 2010 Oct 15
- Depletion of regulatory T cells facilitates growth of established tumors: a mechanism involving the regulation of myeloid-derived suppressor cells by lipoxin A4.
- Authors: Zhang B, Jia H, Liu J, Yang Z, Jiang T, Tang K, Li D, Huang C, Ma J, Shen GX, Ye D, Huang B
- Issue date: 2010 Dec 15
- Targeting CD4+CD25+FoxP3+ regulatory T-cells for the augmentation of cancer immunotherapy.
- Authors: Schabowsky RH, Madireddi S, Sharma R, Yolcu ES, Shirwan H
- Issue date: 2007 Dec
- The significance of Treg cells in defective tumor immunity.
- Authors: Kosmaczewska A, Ciszak L, Potoczek S, Frydecka I
- Issue date: 2008 May-Jun